SPONSORED CONTENT
The 340B program remains essential in ensuring equitable access to crucial medications for vulnerable, underserved populations. The program provides safety net providers with critical resources necessary to expand health related services to low-income and uninsured individuals. Over the past decade, controversy, criticism, and disagreement between manufacturers and program participants, along with regulatory agency indecision, has put the 340B program’s longevity and efficacy into question. To secure its sustainability, all 340B stakeholders must embrace a paradigm shift. Outmoded practices of mistrust and secrecy among stakeholders serve as obstacles to progress and must give way to transparency and collaboration.
Challenges to Sustainability
The sustainability of the 340B program, which is primarily funded through significant discounts from pharmaceutical manufacturers, faces major hurdles if the program continues to be perceived by manufacturers as expanding well beyond the program’s original scope and intent. The program’s expansion, driven by the Affordable Care Act (ACA), has significantly
…
